Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Temporomandibular Disorder

Drug Information

Target Indication

Temporomandibular Disorder

Clinical Trial

Last updated: 9/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Related Pipeline

Postmenopausal Osteoporosis

Small Cell Lung Cancer

Post-Menopausal Osteoporosis

Rheumatoid Arthritis

Breast Cancer

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts